Trial Purpose

The primary objective of the study is to compare MK-2870 combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of MK-2870 and pembrolizumab is superior to pembrolizumab alone with respect to OS.

All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT06170788

When speaking to your doctor, please have the trial identifier number available.

About The Trial

The drug you get will depend on which group you are placed in. This trial has 2 groups.

50% will receive MK-2870 + pembrolizumab

50% will receive pembrolizumab alone

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in approximately 1,000 to 5,000 volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices.

Trial start Icon

Dates

  • Actual study start date December 15, 2023
  • Estimated primary completion date January 25, 2028
  • Estimated study completion date May 27, 2030

Eligibility

Conditions Icon

Conditions

Non-small Cell Lung Cancer

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations